{"product_id":"lyel-marketing-mix","title":"(LYEL) Lyell Immunopharma, Inc. Marketing Mix Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDownload Your Competitive Advantage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Lyell Immunopharma, Inc. 4P's Marketing Mix Analysis explains the company’s product offering, intended use, pricing approach, distribution channels, and promotion tactics in a concise, business-ready format; the page includes a real preview\/sample of the analysis so you can review style and content before buying. Purchase the full version to get the complete, ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eProduct\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGen-R platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLyell Immunopharma, Inc.'s Gen-R platform is an ex vivo genetic reprogramming system built to reduce T cell exhaustion and keep engineered T cells working longer. In FY2025, Lyell still had 0 product revenue, so Gen-R remains the core value driver behind its solid-tumor strategy. That matters because solid tumors account for roughly 90% of adult cancers, and durability is the key gap Gen-R tries to close.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEpi-R platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLyell Immunopharma, Inc.’s Epi-R platform is an ex vivo epigenetic reprogramming system that aims to produce T cells with more stem-like traits, which can support longer anti-tumor activity. In 2025, Lyell remained a clinical-stage company with no marketed products, so Epi-R’s value sits in pipeline execution and future response durability, not current sales.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLYL797\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLYL797 is Lyell Immunopharma, Inc.'s investigational T cell product candidate for major solid tumors, with NSCLC and triple-negative breast cancer as its key targets. In 2022, lung cancer caused about 1.8 million deaths worldwide, and breast cancer had about 2.3 million new cases, showing the size of the unmet need.\u003c\/p\u003e\n\u003cp\u003eFor the Product part of the 4P's, LYL797 sits in a high-value, high-risk pipeline space because both indications still need better cell-therapy options.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eLYL845\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLYL845 is Lyell Immunopharma, Inc.’s investigational T cell product candidate for a broad range of solid tumors, widening its oncology reach beyond earlier programs. In Lyell Immunopharma, Inc.’s 2025 filing, the company reported $151.6 million in cash and marketable securities, supporting ongoing pipeline work. That matters for Product strategy because LYL845 adds a larger tumor opportunity set.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eInvestigational T cell therapy\u003c\/li\u003e\n\u003cli\u003eTargets broad solid tumors\u003c\/li\u003e\n\u003cli\u003eExpands oncology scope\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eNY-ESO-1 program\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLyell Immunopharma’s NY-ESO-1 program targets NY-ESO-1-positive solid tumors, with synovial sarcoma as the lead use case. The program sits in a high-need niche: synovial sarcoma is rare, with about 1,000 new U.S. cases a year.\u003c\/p\u003e\n\u003cp\u003eLyell also has a research and development collaboration and licensing deal with GlaxoSmithKline for this work, which helps fund and de-risk the platform. In Lyell’s latest 10-K, cash and equivalents were $278.8 million as of December 31, 2025.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTarget: NY-ESO-1-positive solid tumors\u003c\/li\u003e\n\u003cli\u003eLead indication: synovial sarcoma\u003c\/li\u003e\n\u003cli\u003ePartner: GlaxoSmithKline\u003c\/li\u003e\n\u003cli\u003eProfile: rare-disease oncology\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLyell’s Pipeline-Driven Product Story Hinges on Clinical Execution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLyell Immunopharma, Inc.’s Product mix is still pipeline-led in FY2025, with no product revenue and cash and marketable securities of $151.6 million at year-end 2025.\u003c\/p\u003e\n\u003cp\u003eGen-R and Epi-R are the core platforms, built to fight T cell exhaustion and improve durability, while LYL797, LYL845, and the NY-ESO-1 program target high-need solid tumors.\u003c\/p\u003e\n\u003cp\u003eThat makes Product highly concentrated on clinical execution, with value tied to better response durability in large markets like NSCLC, triple-negative breast cancer, and synovial sarcoma.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eItem\u003c\/th\u003e\n\u003cth\u003eFY2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eProduct revenue\u003c\/td\u003e\n\u003ctd\u003e0\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash + marketable securities\u003c\/td\u003e\n\u003ctd\u003e$151.6M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eA concise, company-specific 4P’s analysis of Lyell Immunopharma, Inc.’s product, pricing, place, and promotion strategy with real-world biotech context.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eDistills Lyell Immunopharma’s 4Ps into a quick, clear snapshot that eases strategy review and stakeholder alignment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a concise, traceable list of primary sources (clinical filings, SEC reports, peer‑reviewed studies) to speed due diligence and validate Lyell Immunopharma assumptions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePlace\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSouth San Francisco headquarters\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLyell Immunopharma’s main office in South San Francisco, California, sits in a top U.S. biotech hub, close to major peers, labs, and talent. The Bay Area ecosystem supports fast access to research partners and hiring pipelines, which matters for cell therapy work. In fiscal 2025, this site backed research, development, and corporate operations tied to Lyell’s R\u0026amp;D-heavy model.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiotech cluster location\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLyell Immunopharma, Inc. is based in South San Francisco, the core of the Bay Area life sciences cluster, where biotech firms tap a deep talent pool, major venture capital, and lab space. The region hosts over 1,000 life sciences companies and dense research support from Stanford, UCSF, and UC Berkeley. For a capital-intensive oncology biotech, that location helps with hiring, fundraising, and clinical development.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical trial sites\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLyell Immunopharma’s therapies are investigational, so the \"place\" is the study center, not a store. Distribution runs through hospital and oncology trial sites, making this a direct-to-clinic channel with patients enrolled in clinical studies. In this model, access depends on site activation, investigator networks, and protocol enrollment, not retail availability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eU.S. development footprint\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLyell Immunopharma, Inc. is U.S.-based and its development footprint stays close to oncology research, with access shaped by FDA clinical and regulatory review. Its work is centered on advancing cell-therapy programs for major cancer markets, so the main market entry path is proof in trials, then approval. In 2025, that kind of footprint still depends on clinical data, trial milestones, and regulatory timing more than broad commercial rollout.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eU.S.-anchored R\u0026amp;D model\u003c\/li\u003e\n\u003cli\u003eOncology-led pipeline focus\u003c\/li\u003e\n\u003cli\u003eRegulatory and clinical gatekeeping\u003c\/li\u003e\n\u003cli\u003eMarket access starts in trials\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eGSK collaboration channel\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLyell Immunopharma’s GSK channel for NY-ESO-1 is a partner-led route to develop specialized oncology assets, not a direct in-house launch path. The collaboration and licensing deal with GSK gives Lyell access to a larger development and commercialization engine while keeping its focus on engineered cell therapies.\u003c\/p\u003e\n\u003cp\u003eFor place strategy, that matters because the asset moves through GSK’s global network instead of a single-company sales path. Public deal terms for similar biotech licensing models often include upfront cash, milestones, and royalties, which can reduce Lyell’s capital burden and extend runway.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePartner-based development path with GSK\u003c\/li\u003e\n\u003cli\u003eFits Lyell’s specialized oncology focus\u003c\/li\u003e\n\u003cli\u003eCan lower internal launch burden\u003c\/li\u003e\n\u003cli\u003eSupports broader global reach\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLyell Immunopharma’s Biotech Hub and Trial-Driven Access Model\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLyell Immunopharma’s place strategy is centered in South San Francisco, California, inside a biotech cluster that supports hiring, lab access, and research ties. Its therapies reach patients through hospital and oncology trial sites, so access depends on clinical enrollment, not retail channels. The GSK partnership also extends one asset into a partner-led global route.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePlace factor\u003c\/th\u003e\n\u003cth\u003eDetail\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHQ\u003c\/td\u003e\n\u003ctd\u003eSouth San Francisco\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eChannel\u003c\/td\u003e\n\u003ctd\u003eClinical trial sites\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eModel\u003c\/td\u003e\n\u003ctd\u003ePartner-led via GSK\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eLyell Immunopharma, Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the actual Lyell Immunopharma, Inc. 4P's Marketing Mix document you’ll receive instantly after purchase—fully complete and ready to use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePromotion\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSEC filings\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLyell Immunopharma promotes the business through SEC filings, especially its 2025 Form 10-K and quarterly 10-Q reports. These filings spell out pipeline status, cash use, and risk factors, so investors and analysts can track progress without guesswork. They are a core channel for a public company with no product revenue yet, because disclosure is the main way Lyell markets its story.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePress releases\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLyell Immunopharma, Inc. uses press releases to broadcast pipeline and partnership updates, including development milestones and collaboration news. As a pre-commercial biotech with 0 marketed products, this is a key awareness tool, since investor and partner interest drives reach more than paid media. Clear news flow helps keep the company visible while it advances clinical programs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eScientific conferences\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eScientific conferences let Lyell Immunopharma, Inc. build trust at oncology and cell therapy meetings that draw 40,000+ and 22,000+ attendees, respectively. Presenting clinical and translational data helps explain Lyell Immunopharma, Inc.’s platform science, early response signals, and trial design in a way researchers can assess fast. That visibility also matters to investigators and partners who track 2025-2026 development progress.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eClinical trial registries\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eClinical trial registries are a low-cost promotion tool for Lyell Immunopharma, Inc. ClinicalTrials.gov now lists 500,000+ studies, so posting Lyell trials helps patients, physicians, and sites find ongoing work fast. That matters for an R\u0026amp;D-heavy company with no product sales yet, because trial awareness can support enrollment and speed development.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRaises study visibility\u003c\/li\u003e\n\u003cli\u003eHelps recruit patients\u003c\/li\u003e\n\u003cli\u003eSupports site outreach\u003c\/li\u003e\n\u003cli\u003eFits investigational drugs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eGSK partnership visibility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGSK partnership visibility gives Lyell Immunopharma external validation for its NY-ESO-1 program and makes the asset look more credible to investors and biotech peers. Partnership news can lift brand reach fast because it ties Lyell to a larger pharma name and reduces perceived execution risk. In biotech, that enterprise-level signal often matters as much as the science itself.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eValidates NY-ESO-1 program\u003c\/li\u003e\n\u003cli\u003eBoosts market awareness\u003c\/li\u003e\n\u003cli\u003eSignals big-pharma credibility\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThat matters most when Lyell needs trust, follow-on interest, and deal leverage for future trials or licensing talks.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLyell Immunopharma’s Investor-Led Promotion Builds Pipeline Credibility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLyell Immunopharma’s Promotion is investor-led: SEC filings, press releases, conference talks, and ClinicalTrials.gov listings keep pipeline news visible while it has no marketed products. Its 2025 Form 10-K and 2025-2026 trial updates support credibility, and GSK partnership news adds outside validation for the NY-ESO-1 program.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eChannel\u003c\/th\u003e\n\u003cth\u003eUse\u003c\/th\u003e\n\u003cth\u003eData point\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSEC filings\u003c\/td\u003e\n\u003ctd\u003eDisclose pipeline and cash use\u003c\/td\u003e\n\u003ctd\u003e2025 Form 10-K; quarterly 10-Qs\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConferences\u003c\/td\u003e\n\u003ctd\u003eShare clinical data\u003c\/td\u003e\n\u003ctd\u003e40,000+ and 22,000+ attendees\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinicalTrials.gov\u003c\/td\u003e\n\u003ctd\u003eBoost trial visibility\u003c\/td\u003e\n\u003ctd\u003e500,000+ studies listed\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePrice\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNo commercial list price\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLyell Immunopharma, Inc. has no commercial list price because its therapies are still investigational and not sold in the market. In FY2025, it had no marketed product revenue, so patients and hospitals had no public price to compare. Pricing will only matter if a product reaches approval and launch.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical-trial access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLyell Immunopharma, Inc. has no commercial pricing because access to its candidates comes through clinical-trial programs, not retail sales. Trial entry is limited by protocol, site, and eligibility, so the \"price\" to patients is typically zero cash payment, aside from routine trial-related costs. With no approved product revenue reported, value is built through R\u0026amp;D spend and future data, not consumer pricing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGSK licensing economics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLyell's NY-ESO-1 deal with GSK is partner economics, not a retail price: it is a research and development collaboration plus licensing agreement. The value sits in upfront cash, milestones, and possible royalties, while any future product price would be set only if a therapy reaches market. In 2025, the key signal is deal structure, not drug price, because no approved NY-ESO-1 product is selling yet.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePre-commercial revenue model\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLyell Immunopharma, Inc. is still a pre-commercial biotech, so the Price part of its mix is not set by product sales. In FY2025, it had no commercial product revenue, and funding still came from capital markets while R\u0026amp;D drove most costs. That is normal before FDA approval, when price is not the main value lever.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFY2025: no product sales\u003c\/li\u003e\n\u003cli\u003eR\u0026amp;D, not pricing, drives economics\u003c\/li\u003e\n\u003cli\u003eCapital raises fund operations\u003c\/li\u003e\n\u003cli\u003ePricing starts after approval\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eFuture pricing not disclosed\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLyell Immunopharma, Inc. has not disclosed any public pricing policy because it has no approved commercial sales. For July 2026, the price element remains undisclosed, and any future list price would depend on regulatory approval, payer reimbursement, and manufacturing cost per dose.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNo public commercial price set\u003c\/li\u003e\n\u003cli\u003eJuly 2026 status: undisclosed\u003c\/li\u003e\n\u003cli\u003ePrice depends on approval and reimbursement\u003c\/li\u003e\n\u003cli\u003eManufacturing economics will shape pricing\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLyell Immunopharma Has No Commercial Price Yet\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLyell Immunopharma, Inc. has no commercial price yet because it had no approved products in FY2025. Its therapies stayed investigational, so patients paid no list price outside trial settings. Any future price will depend on FDA approval, payer coverage, and manufacturing cost.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eFY2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eProduct revenue\u003c\/td\u003e\n\u003ctd\u003e0\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCommercial list price\u003c\/td\u003e\n\u003ctd\u003eNone\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket status\u003c\/td\u003e\n\u003ctd\u003ePre-commercial\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234602131721,"sku":"lyel-marketing-mix","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/lyel-marketing-mix.webp?v=1785724430","url":"https:\/\/dcfanalyst.com\/products\/lyel-marketing-mix","provider":"DCF Analyst","version":"1.0","type":"link"}